Business Context and Reporting Period
This Form 8-K Current Report was filed by enGene Therapeutics Inc. on May 7, 2026, covering events occurring on May 5 and May 7, 2026. The Company is a clinical-stage biopharmaceutical company focused on developing novel therapies for cancer, specifically detailing updates to its Phase 2 LEGEND trial for detalimogene voraplasmid.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or debt metrics. The only financial data disclosed relates to executive compensation:
- Executive Compensation: Dr. Hussein Sweiti's amended employment agreement includes an annual base salary of $561,750 and an annual bonus opportunity of 40%.
- Severance Terms: The agreement waives the obligation to repay a prior sign-on bonus and allows for resignation with five business days' notice on or after June 1, 2026, while retaining post-termination severance benefits.
Material Changes
The primary material changes reported in this filing are:
- Executive Agreement Amendment: An Amended and Restated Employment Agreement was executed with Dr. Hussein Sweiti, effective May 6, 2026, modifying resignation rights and waiving sign-on bonus repayment obligations.
- Clinical Trial Data Update: The Company announced new interim clinical data for the pivotal cohort of its Phase 2 LEGEND trial regarding detalimogene voraplasmid in high-risk, BCG-unresponsive patients with carcinoma in situ (CIS).
Guidance, Outlook, and Clinical Data
The Company provided interim clinical data as of April 21, 2026, for the Phase 2 LEGEND trial. No forward-looking financial guidance was included in this filing.
Interim Clinical Data Summary (Total Population N=125)
| Metric | Any Time (N=124) | 6 Month (N=121) | 9 Month (N=113) | 12 Month (N=98) |
|---|---|---|---|---|
| Complete Response (CR) Rate | 54.0% (CI: 44.9%, 63.0%) | 43.0% (CI: 34.0%, 52.3%) | 32.7% (CI: 24.2%, 42.2%) | 13.3% (CI: 7.3%, 21.6%) |
| Kaplan-Meier (KM) Estimate | 39.4% | 31.6% | 24.5% | N/A |
Note: CR is defined as negative cystoscopy and negative urine cytology, or positive cystoscopy/cytology with negative bladder biopsy. Data collection and cleaning are ongoing.
Investor Verification Checklist
- Verify the full text of the Amended and Restated Employment Agreement with Dr. Sweiti, which will be filed as an exhibit to the Form 10-Q for the period ended April 30, 2026.
- Review the press release (Exhibit 99.1) and slide presentation (Exhibit 99.2) for detailed methodology regarding the interim clinical data and patient exclusion criteria.
- Monitor upcoming filings for the full financial impact of the executive compensation changes and the Company's cash burn rate relative to the ongoing Phase 2 trial.
- Confirm the timeline for the next data readout or trial milestones for the LEGEND study.